The #1 GLP-3R Research Grade Peptide USA
✓ Fat Burning & Energy Research
Triggers fat-burning pathways for enhanced metabolic activity.
✓ Appetite Control Research
Supports appetite-regulation signaling pathways for reduced intake.
✓ Blood Sugar & Insulin Research
Optimizes glucose control pathways and insulin response activity.
Lab Tested in - USA


For research purposes only · Not for human consumption · Results may vary
256-bit SSL encrypted · All major cards accepted · Ships within 48 hours
Not all research peptide suppliers are the same — here's exactly why researchers keep coming back
| What to Look For |
⭐ PureOne Peptides
|
Generic Supplier |
|---|---|---|
| Purity Level | ~95% | |
| Certificate of Analysis (CoA) | Sometimes | |
| 3rd-Party HPLC Testing | ✗ Self-reported | |
| Same-Day Shipping Available | ✗ | |
| GMP-Grade Synthesis | ✗ | |
| Batch-to-Batch Consistency | Varies | |
| Scientific Research Support | Limited | |
| 30-Day Satisfaction Guarantee | ✗ | |
| Dispatch Speed | Same Day / 48H | 3–7 Days |
GLP-3R is an advanced triple-receptor research peptide engineered to simultaneously target GLP-1, GIP, and glucagon pathways — creating a uniquely comprehensive model for metabolic and energy regulation studies.
Unlike single or dual agonists, GLP-3R is designed to deliver multi-pathway activation, enabling researchers to explore appetite signaling, insulin response, and fat metabolism within a single compound.
Enhanced with a fatty-acid modification, GLP-3R demonstrates extended activity of up to 6 days — allowing for sustained receptor engagement and reduced dosing frequency in long-cycle research protocols.
Based on published study data, here are the areas shown with real breakthroughs.
GLP-3R has demonstrated significant outcomes in body weight studies, with research subjects showing up to 24% reduction over 48 weeks — one of the most notable findings in metabolic research to date.
→Designed to support blood sugar research, GLP-3R enhances insulin-related pathways by activating pancreatic response mechanisms, helping researchers explore improved glycemic regulation.
→Beyond appetite pathways, GLP-3R uniquely activates the glucagon receptor — signaling fat cells to release and oxidize stored lipids, offering a deeper layer of metabolic study.
→Ongoing investigations explore GLP-3R’s role in cardiovascular markers, including blood pressure, lipid profiles, and systemic inflammation — key factors in heart health studies.
→Emerging data suggests GLP-3R may significantly reduce liver fat levels, making it a valuable compound for studying metabolic liver conditions and fatty liver progression.
→GLP-3R’s multi-receptor activity enables advanced pharmacological research, allowing scientists to study differential binding strength across GLP-1, GIP, and glucagon pathways.
→The same receptor targeted by the most powerful weight-loss drugs on the market. Activation slows gastric emptying, reduces hunger signals at the brain level, and modulates glucose-dependent insulin secretion — all in one pathway.
✓ Appetite Suppression · Brain-Level SignalingGLP-3R activates the GIP receptor with nearly 9× the potency of the body's own natural signal. GIP directly controls how fat cells store lipids and how much insulin the pancreas produces — a lever no single-target peptide can pull.
✓ Fat Storage Modulation · Insulin SensitivityNo other research peptide hits the glucagon receptor simultaneously. Glucagon activation directly signals fat cells to release and oxidize stored lipids — effectively adding a turbo mechanism to energy expenditure research that single or dual agonists simply cannot replicate.
✓ Lipolysis Activation · Unique Triple SynergyEngineered with an attached fatty acid chain, GLP-3R demonstrates prolonged stability in research settings — remaining active for up to 6 days. This extended duration reduces dosing frequency while maintaining consistent receptor engagement, making it highly efficient for long-cycle metabolic studies.
✓ ~6-Day Activity · Once-Weekly ProtocolEight research advantages in a single vial · Unmatched in the peptide landscape
Supplied in a sealed vial as lyophilized powder — the gold-standard format for research peptides. Stays stable longer, ships safely, and provides a clean, consistent starting point every time you reconstitute it.
Most peptides reduce hunger OR burn fat — not both. GLP-3R does both simultaneously. The GLP-1 receptor cuts appetite; the glucagon receptor tells fat cells to burn energy. Study both mechanisms in one clean protocol.
Hitting all three receptors at once creates a compounding effect — the combined result is stronger than each pathway individually. Preclinical models confirm GLP-3R outperforms separate compounds given together. One peptide, amplified results.
Activates both GLP-1 and GIP incretin pathways, boosting cellular insulin response. Research data shows meaningful improvements in blood sugar regulation — ideal for diabetes and metabolic disorder research.
Published research shows GLP-3R reduces ANGPTL3/8 — the protein responsible for raising triglycerides and LDL cholesterol — via the glucagon receptor pathway. A powerful tool for cardiovascular and lipid metabolism researchers.
GLP-1 receptor activation reaches the hypothalamus directly, affecting hunger regulation at the brain level — not just in the stomach. GLP-3R opens CNS-metabolic crossover research that single-target peptides simply cannot access.
Validated research models for both obesity and T2D make GLP-3R one of the most versatile metabolic compounds available. Covers two of the largest disease research verticals simultaneously.
Phase 2 trial data confirms that the majority of body weight reduction with GLP-3R comes from fat mass — not lean muscle. This makes it uniquely valuable for body composition research protocols.
GLP-3R isn't a new compound without evidence. It's been studied in one of the largest clinical trials ever conducted for metabolic research — published in the New England Journal of Medicine.
The Phase 2 trial showed up to 24% body weight reduction at 48 weeks — the largest number ever recorded at that point in any drug study. The curve was still going down at study end. The plateau had not been reached.
Research confirms that the vast majority of weight reduction with GLP-3R came from fat mass — not lean tissue. This makes it far more valuable for body composition research than simple calorie restriction models.
Researchers who tested separate compounds for each receptor found the individual results did not stack additively. The fact that one molecule hits all three simultaneously creates a molecular synergy that cannot be replicated by mixing compounds.
Verified purchases · Independent researchers · Real outcomes
Join over 50,000 researchers who receive our lab bulletins — new peptide releases,
exclusive subscriber discounts, and the latest in peptide science.